Notifiable Low Risk Dealing Application Form

Non Plant Research

For dealings involving plants please use the Plant Research NLRD Form found [here](https://services.anu.edu.au/research-support/ethics-integrity/applications-for-approval).

|  |  |
| --- | --- |
| **1** | **Title of Project** |
|  | |

|  |  |
| --- | --- |
| **2A** | **Is this application replacing an existing NLRD?** |
| **NO → GO TO SECTION 3A**  **YES → Current NLRD Approval Number** XX.XX | |

|  |  |
| --- | --- |
| **2B** | **Will all the non-exempt GMOs covered in the above NLRD be covered by this new Dealing?** |
| **YES → GO TO SECTION 3A**  **NO → Select one or both of the following as appropriate**  TheGMOs not covered by this application have been destroyed  TheGMOs not covered by this application have been transferred to another researcher with an NLRD approval that covers dealings with these GMOs.  **Researcher Details**  Name  Workplace Address  Workplace Email Address  Workplace Telephone Number  NLRD Approval Number | |

|  |  |
| --- | --- |
| **3A** | **Project Supervisor** |
| Title Name  Workplace Street Address  Workplace Telephone Number  Workplace Email Address  Relevant experience with GMOs or parent organisms of the kind listed in this application. | |
| Is the Project Supervisor a Visiting Fellow, Postdoctoral Fellow or term appointment?  **NO → GO TO SECTION 3B**  **YES → Start Date** Select  **End Date** Select  **Senior Manager**  Title Name | |

|  |  |  |  |
| --- | --- | --- | --- |
| **3B** | **List of researchers (including the chief investigator) who will work on this project and are authorised to undertake dealings with the GMOs.** | | |
| The Biological Safety and Gene Technology Practices courses are compulsory for **all** ANU researchers working with non-exempt GMOs (academic staff and students). Indicate the date these courses were last completed by each person. Courses must be refreshed every 5 years (completion of exam is sufficient for senior researchers). For courses not yet completed, indicate the dates of the courses for which the researcher has registered.  Undergraduate (non-Honours) students working under constant supervision, do not need to complete the Gene Technology Practices and Biological Safety courses, however they and their supervisors, must sign the declaration stating that they have read, understood and agree to comply with the behavioural requirements for Physical Containment 2 (PC2) facilities as outlined in the training document available at <https://services.anu.edu.au/research-support/ethics-integrity/compulsory-training>  Managers of PC2 laboratories that will be used for this dealing also need to be listed. | | | |
| Name | | Date Biological Safety Course completed | Date Gene Technology Practices Course completed |
| Name | | Date | Date |
| Name | | Date | Date |
| Name | | Date | Date |
| Name | | Date | Date |
| Name | | Date | Date |
| Name | | Date | Date |
| Name | | Date | Date |
| Name | | Date | Date |
| Name | | Date | Date |
| Name | | Date | Date |

|  |  |
| --- | --- |
| **3C** | **Briefly describe the project, including its purpose, aims, and the proposed use of GMOs.**  Include a brief description of all GMOs (including exempt GMOs) that will be used in this dealing.  Using simple language, define acronyms and explain technical terms (1 page maximum). |
|  | |

|  |  |
| --- | --- |
| **3D** | **Types of Exempt Dealings** |
| Below are Exempt Dealings listed in the Gene Technology Regulations 2001 (amended 2019) that are likely to be relevant to work with GM micro-organisms and/or GM animals  N.B. The following categories exclude vectors carrying genes encoding toxins and pathogenic determinants able to cause harm to humans or animals or an uncharacterized nucleic acid from a toxin-producing organism or viral sequence (unless specific conditions are met). | |
| Indicate the kinds of exempt dealings that will be used in this project  Routine cloning in *E. coli* using non-conjugative plasmid vectors.  Routine cloning in yeast (*Saccharomyces cerevisiae* or *Pichia pastoris*) or a Baculovirus expression vector system (Sf9 or Hi-5 insect cells) for the purposes of protein expression or protein interaction studies.  Routine transformation of tissue culture cells. Describe any viral packaging cell line(s), replication defective viral vector(s) unable to transduce human cells or transgene(s) carrying viral sequences.  Cell line(s) Provide description  Vector(s) Provide description  Transgene(s) Provide description  A dealing with a GMO carrying a gene knockout generated by unguided repair of breaks induced in genomic DNA by a site-directed nuclease, providing no transgenes were inserted or none remain.  Other exempt dealings Provide Description | |

|  |  |
| --- | --- |
| **4** | **Description of non-exempt GMOs** |
| **4A** | **If any of the following genetic modifications apply to this application do not continue with this application.** [**Contact**](mailto:rdna.officer@anu.edu.au) **the secretary of the rDNA monitoring committee for further advice.** |
| * Cloning of a gene encoding a toxin in a non-exempt host-vector system. * Expression of a toxin gene. * Cloning of an uncharacterised gene from a toxin-producing organism in a non-exempt host-vector system * Expression of a gene that confers an oncogenic modification or immunomodulatory effect in humans using a replication-defective viral vector able to transduce human cells. * A genetic modification of a pathogen that provides an advantage, adds a new host or new mode of transmission, or increases its virulence, pathogenicity of transmissibility compared to the unmodified pathogen. * Genetic modification of a risk group 3 micro-organism. * A genetic modification designed to generate a [gene-drive](http://www.ogtr.gov.au/internet/ogtr/publishing.nsf/Content/53139D205A98A3B3CA257D4F00811F97/$File/OGTR%20guidance%20on%20gene%20drives.pdf) in the parent organism. * Genetic modification of a micro-organism designed to generate a gene-drive in another organism. | |

|  |  |
| --- | --- |
| **4B** | **Name(s) of the organism(s) being modified.**  **I**nclude both common and species names. |
|  | |

|  |  |
| --- | --- |
| **4C** | **Vector(s) and methods used for transfer of genetic material if the GMOs will be generated as part of the proposed dealings.**  Include references for novel vectors or novel methods of transfer.  For vectors sourced commercially, include company name(s). |
|  | |

|  |  |
| --- | --- |
| **4D** | **Modified trait(s) and gene(s) responsible**  Do not include promoters or terminators. |
| Antibiotic resistance genes including but not limited to genes conferring resistance to Ampicillin, Chloramphenicol, Gentamicin, Kanamycin, Neomycin or Tetracycline.  Reporter genes including but not limited to DsRed and derivatives, GFP and derivatives, GUS (beta glucuronidase), and luciferase.  Over-expression, inducible expression, attenuation or silencing of endogenous genes.  Knockouts generated by  Insertional mutagenesis  Site specific recombination e.g. Cre/Lox, Flp/Frt  Genome editing e.g. CRISPR/Cas9, TALENs, other than that included in 3D  Describe the knockout system and any transgenes inserted other than antibiotic resistance genes and reporter genes  Provide Description  Disease attenuation (reduced ability to replicate and cause disease).  Provide Details  Other  Indicate the modified traits and genes responsible | |

|  |  |
| --- | --- |
| **4E** | **Will non-GM organisms to be used in association with the GMOs covered by this dealing?**  Do not include the non-GM parents used to generate the GMOs covered by this dealing. |
| **NO → GO TO SECTION 4F**  **YES → Indicate the non-GM organisms that will be used and briefly explain how they will be used.**  Provide Details | |

|  |  |
| --- | --- |
| **4F** | **Will non-exempt GM organisms covered by another dealing (NLRD or DNIR) to be used in association with the GMOs covered by this dealing?** |
| **NO → GO TO SECTION 4G**  **YES → NLRD Approval/DNIR Licence Number** SelectXX.XX  Briefly explain how the GMOs from the other dealing will be used in conjunction with the GMOs from this dealing.  Provide Details | |

|  |
| --- |
|  |

|  |  |
| --- | --- |
| **4G** | **Type of Dealing** |
| Below are the kinds of Notifiable Low Risk Dealings listed in the Gene Technology Regulations 2001 (amended 2019). Select the statement(s) that best describes the dealing(s) with the GMOs. | |
| **Notifiable Low Risk Dealings that may be conducted in certified Physical Containment Level 1 facilities.** | |
| **(a)** A dealing involving a genetically modified laboratory guinea pig, a genetically modified laboratory mouse, a genetically modified laboratory rabbit or a genetically modified laboratory rat, unless:   1. an advantage is conferred on the animal by the genetic modification; or 2. the animal is capable of secreting or producing an infectious agent as a result of the genetic modification;   **(c)** a dealing involving virions of a replication defective vector derived from *Human adenovirus* or from *Adeno associated virus*, either without a host or with a host mentioned in item 9 of Part 2 of Schedule 2, if the donor nucleic acid:   1. cannot restore replication competence to the vector; and   **(ii)** does not confer an oncogenic modification or immunomodulatory effect in humans. | |
| **Notifiable Low Risk Dealings that may be conducted in certified Physical Containment Level 2 facilities.** | |
| (a) A dealing involving whole animals (including non-vertebrates) that:  **(i)** involves genetic modification of the genome of the oocyte or zygote or early embryo by any means to produce a novel whole organism; and  **(ii)** does not involve any of the following:  **(A)** a genetically modified laboratory guinea pig;  **(B)** a genetically modified laboratory mouse;  **(C)** a genetically modified laboratory rabbit;  **(D)** a genetically modified laboratory rat;  **(E)** a genetically modified *Caenorhabditis elegans*; | |
| (aa) A dealing involving a genetically modified laboratory guinea pig, a genetically modified laboratory mouse, a genetically modified laboratory rabbit, a genetically modified laboratory rat, or a genetically modified *Caenorhabditis elegans*, if:   1. the genetic modification confers an advantage on the animal; and 2. the animal is not capable of secreting or producing an infectious agent as a result of the genetic modification; | |
| (c) A dealing involving a host/vector system not mentioned in paragraph 1.1(c) or Part 2 of Schedule 2, if neither host nor vector has been implicated in, or has a history of causing, disease in otherwise healthy:   1. human beings; or 2. animals; or 3. plants; or 4. fungi; | |
| **(d)** A dealing involving a host/vector system not mentioned in Part 2 of Schedule 2, if:   1. the host or vector has been implicated in, or has a history of causing, disease in otherwise healthy:   **(A)** human beings; or  **(B)** animals; or  **(C)** plants; or  **(D)** fungi; and  **(ii)** the genetic modification is characterized; and   * 1. the characterization of the genetic modification acid shows that it is unlikely to increase the capacity of the host or vector to cause harm;   *Example:* A genetic modification would not comply with subparagraph (iii) if, in relation to the capacity of the host or vector to cause harm, it:   * provides an advantage; or * adds a potential host species or mode of transmission; or * increases virulence, pathogenicity or transmissibility. | |
| **(e)** A dealing involving a host/vector system mentioned in Part 2 of Schedule 2, if the donor nucleic acid:  **(i)** is characterised, and the characterisation shows that it may increase the capacity of the host or vector to cause harm; or  **(ii)** is uncharacterised nucleic acid from an organism that has been implicated in, or has a history of causing, disease in otherwise healthy;   * + - * 1. human beings; or         2. animals; or         3. plants; or         4. fungi; | |
| (f) A dealing involving a host/vector system mentioned in Part 2 of Schedule 2 and producing more than 25 litres of GMO culture in each vessel containing the resultant culture, if:   * + - 1. the dealing is undertaken in a facility that is certified by the Regulator as a large scale facility; and       2. the donor nucleic acid satisfies the conditions set out in subitem 4 (2) of Part 1 of Schedule 2; | |
| (g) A dealing involving complementation of knocked-out genes, if the complementation is unlikely to increase the capacity of the GMO to cause harm compared to the capacity of the parent organism before the genes were knocked out;  *Example*  A dealing would not comply with paragraph (g) if it involved complementation that, in relation to the parent organism:   * provides an advantage; or * adds a potential host species or mode of transmission; or * increases its virulence, pathogenicity or transmissibility. | |
| **(h)** A dealing involving shot-gun cloning, or the preparation of a cDNA library, in a host/vector system mentioned in items 1 to 6 of the table in Part 2 of Schedule 2, if the donor nucleic acid is derived from either:  **(i)** a pathogen; or  **(ii)** a toxin-producing organism; | |
| **(i)** A dealing involving virions of a replication defective viral vector unable to transduce human cells and a host not mentioned in Part 2 of Schedule 2, if the donor nucleic acid cannot restore replication competence to the vector; | |
| **(j)** A dealing involving the introduction of a replication defective non-retroviral vector able to transduce human cells, other than a dealing mentioned in paragraph 1.1 (c), into a host mentioned in Part 2 of Schedule 2, if the donor nucleic acid cannot restore replication competence to the vector; | |
| (k**)** A dealing involving the introduction of a replication defective non-retroviral vector able to transduce human cells into a host not mentioned in Part 2 of Schedule 2, if:  **(i)** the donor nucleic acid cannot restore replication competence to the vector; and  **(ii)** the donor nucleic acid does not confer an oncogenic modification or immunomodulatory effect in humans; | |
| **(l)** A dealing involving virions of a replication defective retroviral vector able to transduce human cells, either without a host or with a host mentioned in Part 2 of Schedule 2, if:  **(i)** all viral genes have been removed from the retroviral vector so that it cannot replicate or assemble new virions without these functions being supplied *in trans*; and  **(ii)** viral genes needed for virion production in the packaging cell line are expressed from independent, unlinked loci with minimal sequence overlap with the vector to limit or prevent recombination; and  **(iii)** either:  **(A)** the retroviral vector includes a deletion in the Long Terminal Repeat sequence of DNA that prevents transcription of genomic RNA following integration into the host cell DNA; or  **(B)** the packaging cell line and packaging plasmids express only viral genes *gagpol*, *rev* and an envelope protein gene, or a subset of these; | |
| **(m)** A dealing involving virions of a replication defective retroviral vector able to  transduce human cells and a host not mentioned in Part 2 of Schedule 2, if:  **(i)** the donor nucleic acids does not confer an oncogenic modification or immunomodulatory effect in humans; and  **(ii)** all viral genes have been removed from the retroviral vector so that it cannot replicate or assemble new virions without these functions being supplied *in trans*; and  **(iii)** viral genes needed for virion production in the packaging cell line are expressed from independent, unlinked loci with minimal sequence overlap with the vector to limit or prevent recombination; and  **(iv)** either  **(A)** the retroviral vector includes a deletion in the Long Terminal Repeat sequence of DNA that prevents transcription of genomic RNA following integration into the host cell DNA; or  **(B)** the packaging cell line and packaging plasmids express only viral genes *gagpol*, *rev* and an envelope protein gene, or a subset of these. | |

|  |  |
| --- | --- |
| **5** | **Risk Assessment and Management**  Will non-exempt GM micro-organisms able to infect humans or GM parasites able to infect humans be used in this dealing? |
| **NO → GO TO SECTION 5C**  **YES → Continue to SECTION 5A** | |

|  |  |
| --- | --- |
| **5A** | **Health and Safety of Staff**  In the event of exposure to these GM micro-organisms or GM parasites, what would the health and safety consequences be for the affected staff?  Your answer should address the effects of the genetic modification on pathogenicity. |
|  | |
| What features of the GMO(s) minimise possible harm arising from exposure e.g. use of attenuated pathogens, antibiotic sensitivity etc.? | |
|  | |
| What control measures will be used to minimise possible harm arising from exposure e.g. vaccination, use of available and effective antibiotics etc.?  **Do not** include measures designed to reduce the risk of exposure. | |
|  | |

|  |  |
| --- | --- |
| **5B** | **Health and Safety of General Public**  In the event of an unintentional release of these GM micro-organisms or GM parasites into the environment, would the health and safety consequences for the general public be the same or less than those outlined in 5A for staff exposed to the GMO(s)? |
| **YES → GO TO SECTION 5C**  **NO → Provide details below** | |
|  | |

|  |  |
| --- | --- |
| **5C** | **Environment**  In the event of an unintentional release of GMOs covered by this dealing into the environment, what consequences would there be for the environment i.e. for animals, plants etc.?  Your answer should address the effects of the genetic modification on the GMO relative to its parent. |
|  | |
| What features of the GMO(s) minimise possible harm arising from unintentional release e.g. poor environmental survival, local absence of a host or vector for an animal pathogen or pest etc.? | |
|  | |
| What control measures will be used to minimise possible harm arising from unintentional release e.g. vaccination, use of available and effective antibiotics or pesticides etc.?  **Do not** include measures designed to reduce the risk of unintentional release.  **Do not** include immediate steps that will be taken to deal with an unintentional release. These steps should be listed in 5O. | |
|  | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **5D** | **Indicate the facility type and certification numbers for all the facilities to be used in this dealing. If you are using facilities at other institutions they should also be listed here.**  N.B. The ANU IBC cannot provide approval for work to be conducted in facilities controlled by another IBC or by researchers at another institution. You must have the approval of the other institution’s IBC before beginning work in their facilities. | | | |
| **Building or Facility Name** | | **Room Number** | **Facility type** | **Certification number** |
| Name | | Room | Select Type | Cert XXXX |
| Name | | Room | Select Type | Cert XXXX |
| Name | | Room | Select Type | Cert XXXX |
| Name | | Room | Select Type | Cert XXXX |
| Name | | Room | Select Type | Cert XXXX |

|  |  |
| --- | --- |
| **5E** | **Is non-GM or exempt GM work conducted in any of the facilities listed above?** |
| **NO → GO TO SECTION 5F**  **YES → Is this work treated as PC2 work i.e. all organisms treated as if they were non-exempt GMOs?**  **YES → GO TO SECTION 5F**  **NO → Continue below**  Please outline the procedures that will be used to prevent cross contamination of non-GM work or exempt GM work by non-exempt GMOs. These could include   * spatial or temporal separation * disinfection of work surfaces or equipment between experiments * making personnel undertaking non-GM or exempt GM work aware that non-exempt work is taking place in the same facility and the need to prevent cross contamination.   These procedures must be documented in your facility manual(s). | |
|  | |

|  |  |
| --- | --- |
| **5F** | **Will any work with live GM animals or animals infected with non-exempt GMOs be carried out in laboratories?** |
| **NO → GO TO SECTION 5G**  **YES → Continue below** | |
| Which laboratories will be involved? | |
|  | |
| Outline the nature of the work with GM animals or animals infected with non-exempt GMOs for each of the laboratories involved. | |
|  | |
| What is the justification for use of laboratories rather than animal facilities? | |
|  | |
| What precautions will be taken to minimise escape of the animals into the laboratory or beyond? | |
|  | |

|  |  |
| --- | --- |
| **5G** | **Do you intend crossing GMOs expressing different transgenes to one another?** |
| **NO → GO TO SECTION 5I**  **YES → List the kinds of crosses proposed below**   * Exclude crosses required as part of the procedure used to generate a GMO e.g. using the Cre/Lox system to generate knockout mice, which should be listed in 4D. * Exclude crosses required for the maintenance of the GMO or crosses to non-GMOs. The progeny of these crosses are considered the same as the original GMO. * Exclude crosses to GMOs expressing only selectable markers and/or commonly used reporter genes e.g. GFP, luciferase, galactosidase, glucuronidase.   All crosses (including those excluded above) should be recorded and the crossing record made available for inspection if required. | |
|  | |

|  |  |
| --- | --- |
| **5H** | **Are the risks to health and safety of people or to the environment (i.e. the likelihood and consequences of exposure or unintentional release) expected to be different for the progeny of any crosses listed in Part 5G than the combined risks for the parent GMOs?**  N.B. If you discover the progeny have a different phenotype, and therefore different associated risks than expected, you must discontinue any further experimental work with the progeny and notify the ANU IBC to have your dealing re-evaluated. |
| **NO → GO TO SECTION 5I**  **YES → Continue below** | |
| What are the altered risks? | |
|  | |
| What additional actions will be taken or procedures put in place to minimise the altered risks? | |
|  | |

|  |  |  |
| --- | --- | --- |
| **5I** | **Will training be required for animal handling e.g. training programs delivered by APF or by your laboratory/school e.g. Basic Mouse Handling.**  N.B. A record of this training must be documented in your facility manual. | |
| **NO → GO TO SECTION 5J**  **YES → Continue below** | | |
| **ANU Animal Courses** | | **Date Completed** |
| ANML03 Animal Awareness Program | | Date |
| Choose a Course | | Date |
| Choose a Course | | Date |
| **Additional Animal Courses/Training** | | **Date Completed** |
| Name | | Date |
| Name | | Date |
| Name | | Date |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **5J** | **Will the dealing(s) involve the injection of GM micro-organisms into animals?** | | | |
| **NO → GO TO SECTION 5K**  **YES → Continue below** | | | | |
| **GM micro-organism** | | **Animal** | **Injection technique** | **SOP and Risk Assessment numbers** (where applicable) |
| Name | | Name | Select Technique | SOP or RA number or both |
| Name | | Name | Select Technique | SOP or RA number or Both |
| Name | | Name | Select Technique | SOP or RA number or Both |
| Please ensure training in relevant injection techniques is recorded in 5I.  Attach copies of risk assessments and experimental protocols (SOPs) referenced above.  N.B. These attachments become part of the application and are therefore also subject to review. | | | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **5K** | **How will GMO’s be transported (e.g. between facilities, to storage facilities outside of a PC2 facility, transportation of waste or import/export)?**  The answer to this question provides confirmation that you understand the [OGTR Guidelines for the Transport, Storage and Disposal of GMOs](http://www.ogtr.gov.au/internet/ogtr/publishing.nsf/Content/tsd-guidelines-toc) and have considered these requirements for the transport of each class of GMO covered by this dealing.  The description of transport must include information about the type of containment (e.g. double contained in unbreakable containers with the outer container sealed), labelling and accounting procedures (if appropriate). | | |
| **GMO** e.g. mouse, bacteria, virus | | **Description of Transport** | **SOP number** (where applicable) |
| Name | | Description | SOP number |
| Name | | Description | SOP number |
| Name | | Description | SOP number |
| Attach copies of experimental protocols (SOPs) referenced above.  N.B. These attachments become part of the application and are therefore also subject to review. | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **5L** | **List the proposed storage location(s) of non-exempt GMOs.**  Do not include facilities used to house live animals or grow cultures. | | | |
| **GMO** e.g. mouse, bacteria, virus | | **Material stored**  e.g. frozen embryos | **Storage location** | **Type of Storage Unit** |
| Name | | Type | Location | Select |
| Name | | Type | Location | Select |
| Name | | Type | Location | Select |
| Are any of the storage units located outside of a PC2 Facility? | | | | |
| **NO → GO TO SECTION 5M**  **YES → Continue below** | | | | |
| Which storage unit is located outside of a PC2 Facility? | | | | |
|  | | | | |
| How is access to the storage unit limited to authorised personnel? | | | | |
|  | | | | |
| How is the storage unit labelled? | | | | |
|  | | | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **5M** | **What methods will be used to dispose of GMOs covered by this dealing or decontaminate GM waste generated by this dealing?**  The answer to this question provides confirmation that you understand the [OGTR Guidelines for the Transport, Storage and Disposal of GMOs](http://www.ogtr.gov.au/internet/ogtr/publishing.nsf/Content/tsd-guidelines-toc) and have considered these requirements for the disposal of each class of GMO covered by this dealing. | | |
| **GMO/GM Waste** | | **Method of Disposal** | **SOP number** (where applicable) |
| Select | | Description | SOP number |
| Select | | Description | SOP number |
| Select | | Description | SOP number |
| Attach copies of experimental protocols (SOPs) referenced above  N.B. These attachments become part of the application and are therefore also subject to review. | | | |

|  |  |
| --- | --- |
| **5N** | **Do you have any extra measures or controls in place beyond standard PC2 requirements to prevent exposure to or unintentional release of GMOs covered by this dealing?** |
| **NO → GO TO SECTION 5O**  **YES → Provide details below** | |
|  | |

|  |  |
| --- | --- |
| **5O** | **What steps will you take in the event of an unintentional release of GMOs covered by this dealing?** |
|  | |

|  |  |  |
| --- | --- | --- |
| **6** | **Declarations**  **IMPORTANT:** Do not sign until the application has been finalised following review by the IBC and you are requested to do so by the Secretary of the IBC. | |
| **Project Supervisor Declaration**  By submitting this application to The Australian National University Recombinant DNA Monitoring Committee (the ANU Institutional Biosafety Committee), I declare the following   * I accept responsibility for the conduct of the research outlined in this application in accordance with the [Gene Technology Act 2000](https://www.legislation.gov.au/Details/C2016C00792) and [Gene Technology Regulations 2001](https://www.legislation.gov.au/Details/F2016C00615) and subsequent Amendments. * I will ensure that this research project is conducted in accordance with the behavioural requirements set out in the [Guidelines for Certification of a Physical Containment Facility](http://www.ogtr.gov.au/internet/ogtr/publishing.nsf/Content/cert-pc2-1) and the [Guidelines for Transport, Storage and Disposal of GMOs](http://www.ogtr.gov.au/internet/ogtr/publishing.nsf/Content/tsd-guidelines-toc/$FILE/tsd-guidelines.pdf) and ensure safe work practices at all times. * I confirm that that all staff and students involved in this dealing have undertaken training in Gene Technology Practices and Biological Safety or will do so before commencing work on this dealing and that training records are retained within the laboratory. Undergraduate (non-Honours) students working under constant supervision who have not completed the Gene Technology Practices and Biological Safety courses, and their supervisors, must sign the declaration stating that they have read, understood and agree to comply with the behavioural requirements for Physical Containment 2 (PC2) facilities as outlined in the training document available at <https://services.anu.edu.au/research-support/ethics-integrity/compulsory-training>. * I will ensure that all personnel working on this project are provided with copies of the approved NLRD and any associated risk assessments and SOPs * I agree to maintain a register of all GMOs covered by this dealing. * I will submit a report of this dealing once every 12 months during the life of this project and understand that ongoing IBC approval of this dealing is subject to meeting this annual reporting requirement. * I will inform the IBC of any proposed changes to the scope of the work described in this application. * I declare that to the best of my/our knowledge, having made reasonable inquiries, the information herein is true and correct. I understand that providing misleading information to the OGTR, either directly or indirectly, deliberately or otherwise, is an offence under Commonwealth law. * On completion of this project or termination of employment, I will ensure that all GMOs covered by this NLRD are destroyed or stored under an appropriate NLRD or transferred to another researcher with an appropriate NLRD. I will complete a Dealing Expiry/Discontinuation report at the end of my research or by the expiry date of the NLRD. I will ensure that the location of stored or transferred GMOs is clearly documented in this report.   Signature Printed Name Full Name Date Select | | |
| **Senior Manager Declaration**  (Required if the Project Supervisor is a Visiting Fellow, Post-doctoral Fellow or Term Appointment)  As the Senior Manager responsible for the research activities of the project supervisor, I acknowledge my responsibility to ensure that all GMOs covered by this NLRD are appropriately destroyed, stored or transferred at the end of the project supervisor’s tenure. I will ensure that a Dealing Expiry/Discontinuation report is completed for this project and that the location of all GMOs from this project is clearly documented and communicated to the IBC.  Signature Printed Name Full Name Date Select | | |
| **IBC Declaration**  The IBC has evaluated this dealing and agrees that it is a NLRD as specified by Schedule 3, Part 1 or Part 2 of the Gene Technology Regulations 2001 (Amended 2019). | | |
| Name of IBC | | The Australian National University Recombinant DNA Monitoring Committee |
| Name of IBC Chair | | Prof. David Jones |
| Signature Date Select | | |